Loading…
← CockpitCompetitor Analysis › 9627.T Ain Holdings Inc.Open in the cockpit ↗

Ain Holdings Inc.9627.TCompetitor analysis, valuation and peers

Japan · JPY·Consumer Staples›Drugstore Chains

Japan's largest dispensing-pharmacy operator, also runs drugstores, based in Hokkaido.

≈ A Japanese CVS Health (pharmacy-benefit-adjacent) equivalentMomentum neutral 53
Mkt cap
$1.25B
US dollars, full cap
Free float
66%
of shares outstanding
$/day
$3.76M
20-day average traded
Fwd P/E
13.8×
forward earnings
ROIC−WACC
+2.7 pp
WACC 5.0%
Hurdle
-23 pp
Req g minus delivered
Next earnings
22 days
10 Dec 2026
Close · JPY¥5,710
1D-0.9%
1W+3.6%
1M+1.1%
3M-7.6%
6M+2.1%
YTD-14.6%
1Y-11.8%
ATR %2.5%
52w lowhigh21.6% off high

What Ain does

Japan's largest dispensing-pharmacy operator, also runs drugstores, based in Hokkaido.

Paid for most dispensing through Japan's national health insurance: the pharmacy collects a government-set dispensing fee plus the margin between the official drug price and its purchase price. The fee schedule is revised every two years, so policy sets income more than competition does. Locations next to clinics and hospitals bring the prescriptions.

In one line: A Japanese CVS Health (pharmacy-benefit-adjacent) equivalent.

Products and services

  • Dispensing pharmacy services
  • Drugstore retail (OTC, cosmetics)

Customers

  • Prescription drug patients
  • Retail drugstore consumers

Where it sits in the supply chain

  • Consumer Staples
  • Retail pharmacy
  • Dispensing pharmacy & drugstore retail

What could go right

  • Aging population driving prescription drug dispensing demand

What could go wrong

  • Drug-reimbursement price regulation
  • Drugstore sector price competition

Moat: narrow (scale, regulatory licence, distribution). Largest dispensing-pharmacy network in Japan, tied to hospital referral relationships nationwide.

Headquarters: Sapporo, Japan · Founded: 1990 · Employees: 17,332

Named competitors

Ain at a glance

Size Ain (9627.T) is a Japan Consumer Staples company (Drugstore Chains) with a market value of $1.25B, the 644th largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥5,710 on 18 Nov 2026.

Performance Over six months the shares gained 2.1%, against +2.6% for the median peer and -1.4% for the Japan market (cap-weighted) — 8th lowest of 18 in its peer set.

Growth Revenue grew 42.3% over the last twelve months (peer median +5.3%); the operating margin is 4.4% (peer median 4.8%).

Valuation It trades at 13.8× forward earnings against a peer median of 16.6× (2nd cheapest of 12).

Price implies For today's price to make sense, revenue must grow about -6% a year for seven years (Req g). Recent delivered growth is +17%, so the hurdle is -23 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 2.7 points above its cost of capital (5.0% WACC).

Next results Next results expected around 10 Dec 2026 (exchange calendar; dates can move).

Relative performance

9010011021 May 202621 Aug 202618 Nov 2026Peer median 1049627.T 103
Six months, rebased to 100: Ain against the median of its 17 peers (local-currency closes).

Ain financials

Reported figures in JPY; fiscal year ends 2026-04-30. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue¥692B¥648B¥457B¥400B¥359B
Revenue growth—+42%+14%+11%—
Gross profit¥100B¥93.6B¥65.6B¥53.4B¥47.9B
EBITDA¥54.3B¥52.0B¥31.0B¥31.2B¥25.8B
Net income¥17.3B¥17.3B¥9.26B¥11.4B¥9.23B
Free cash flown/a¥21.0B¥15.2B¥13.9B¥10.7B
Capital expendituren/a¥17.2B¥12.2B¥12.5B¥12.2B
Total debt¥167B¥172B¥39.0B¥6.75B¥8.74B

Quarterly statements and history in the cockpit →

Ain competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-20%0%3148002727603883MEDPLUS3014089267301017266430346035900027889989GRDN76496032330005046039399627.T6-month return →1-month return →
Up and to the right = strong over both horizons. Ain is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%10×20×30×002727603883MEDPLUS926730346035909989GRDN76499627.TRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Ain is the large dot.

Capital: growth delivered against growth the price implies

-10%0%+10%+20%0%20%3148002727603883MEDPLUS301408301017266430346035900027889989GRDN76499627.TGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Ain is the large dot.

Ain competitors and peer comparison

Head to head with its named competitors (9627.T vs 7649.T vs 9989.T)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Ain 9627.T$1.25B+2%+42%4%13.8×-6.5%
Sugi 7649.T$3.46B-9%+9%5%17.9×-9.0%
Sundrug 9989.T$3.07B+10%+4%6%14.9×-7.3%

How Ain compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Ain against its 17 peers (data as of 18 Nov 2026)
Measure9627.TPeer medianRank in peer set
1-month return+1.1%+1.6%9th lowest of 18
6-month return+2.1%+2.6%8th lowest of 18
Distance from 52-week high-21.6%-17.0%9th lowest of 18
Revenue growth (TTM)+42.3%+5.3%2nd highest of 18
Operating margin4.4%4.8%7th lowest of 18
Forward P/E13.8×16.6×2nd cheapest of 12
Growth the price implies (Req g, 7 yrs)-6.5%-7.5%7th most demanding of 16
Growth delivered (Del g)+16.9%+10.9%4th highest of 16
Hurdle (Req g minus delivered)-23.3 pp-19.5 pp3rd least demanding of 16
ROIC minus cost of capital+2.7 pp+7.0 pp8th lowest of 18
EV / EBITDA5.8×7.5×2nd cheapest of 8
Net debt / EBITDA2.1×-0.3×most indebted of 9

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Ain 9627.TJapan$1.25B+2%+42%4%13.8×-6.5%+16.9%
Create SD 3148.TJapan$1.32B+3%+9%5%n/a-11.5%+8.0%
Yixintang Pharmaceutical 002727.SZChina$1.16B+4%-2%3%16.6×-16.0%+6.5%
LBX Pharmacy Chain Joint Stock 603883.SSChina$1.71B+13%+3%5%16.1×-10.7%+9.7%
MedPlus Health Services MEDPLUS.NSIndia$771M-36%+21%4%33.9×18.6%+17.6%
Anhui Huaren Health Pharmaceutical 301408.SZChina$745M-32%+15%8%n/a-7.5%+23.3%
Genky DrugStores 9267.TJapan$728M+3%+8%5%13.9×n/an/a
Shu Yu Civilian Pharmacy 301017.SZChina$701M-11%+9%2%n/a1.1%+17.4%
Cawachi 2664.TJapan$562M+31%-1%2%n/a-6.1%0.0%
Qol 3034.TJapan$561M+26%+5%6%10.5×-16.6%+12.4%
Beijing Konruns Pharmaceutical 603590.SSChina$558M-33%-1%17%19.0×12.4%+2.7%
Luyan Pharma 002788.SZChina$514M-32%+3%3%n/a-0.4%+6.5%
Sundrug 9989.TJapan$3.07B+10%+4%6%14.9×-7.3%+5.8%
Guardian Pharmacy Services GRDNUnited States$3.09B+30%+5%6%33.3×4.4%+16.8%
Sugi 7649.TJapan$3.46B-9%+9%5%17.9×-9.0%+10.9%
DaShenLin Pharmaceutical 603233.SSChina$3.64B+10%+7%8%15.9×-9.5%+13.6%
Landfar Bio-medicine 000504.SZChina$351M-22%+497%-2%n/an/an/a
Yifeng Pharmacy Chain 603939.SSChina$4.84B+16%+5%10%17.2×-9.3%+13.2%

Questions

Who are Ain's main competitors?
Named competitors: Sugi Holdings (7649.T), Sundrug (9989.T), Nihon Chouzai (private or unlisted). The cockpit's measured peer set (industry) also includes Create SD (3148.T), Yixintang Pharmaceutical (002727.SZ), LBX Pharmacy Chain Joint Stock (603883.SS), MedPlus Health Services (MEDPLUS.NS), Anhui Huaren Health Pharmaceutical (301408.SZ), Genky DrugStores (9267.T).
Is Ain expensive compared with its peers?
On forward p/e it trades at 13.8× against a peer median of 16.6×, 2nd cheapest of 12 in its peer set. For today's price to make sense, revenue must grow about -6% a year for seven years (Req g). Recent delivered growth is +17%, so the hurdle is -23 pp: the price already allows for a slowdown.
How has Ain stock performed?
Over six months to 18 Nov 2026 the shares returned +2.1% against +2.6% for the median peer; over one year -11.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.